The new indication makes Ozempic the first glucagon-like peptide-1 receptor agonist (GLP-1RA) available for people with T2D ...

Sonnet BioTherapeutics has received a patent from the European Patent Office (EPO) for its fully human albumin binding (FHAB) ...

A proposed ban on PFAS chemicals is being challenged over concerns about potential supply chain disruption in the ...

The FDA has granted RMAT designation to Beacon Therapeutics’ gene therapy, laru-zova, for treating X-linked retinitis ...

ITM Radiopharma’s Phase III trial of its targeted radiotherapeutic for patients with Grade 1 or 2 gastroenteropancreatic ...

A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Can-Fite BioPharma has secured a US patent for Namodenoson, its lead drug candidate, for use as an anti-obesity treatment.

Arena International’s Outsourcing in Clinical Trials West Coast 2025 will discuss patient centricity, diversity, and ...

Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...

AB2 Bio has made an option and licensing agreement with Nippon Shinyaku, granting the latter the option to commercialise ...

This study reinforces the significance of intensive glycaemic control and is a paradigm shift in managing the disease and its ...